SEC Eyes Trading Around Inspire's Announcement Of Failed Diquafosol Study
This article was originally published in The Pink Sheet Daily
Executive Summary
A drop in the firm's stock on the morning that unsuccessful Phase III trial results for diquafosol tetrasodium were announced prompts a formal investigation by the Securities & Exchange Commission.